Article Text

PDF

146
BRAIN ATROPHY AND DISEASE-FREE STATUS OVER 4 YEARS OF FREEDOMS STUDY
  1. Eli Silber1,
  2. Ernst-Willhelm Radue2,
  3. Nicola De Stefano3,
  4. Paul O'Connor4,
  5. Daniela Piani-Meier5,
  6. Gordon Francis6,
  7. Davorka Tomic5,
  8. Ludwicg Kappos7
  1. 1King's College Hospital, London
  2. 2Medical Image Analysis Center, University Hospital Basel, Basel, Switzerland
  3. 3University of Siena, Siena, Italy
  4. 4St. Michael's Hospital, Toronto, ON, Canada
  5. 5Novartis Pharma AG, Basel, Switzerland
  6. 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
  7. 7University of Basel, Basel, Switzerland

Abstract

Objective Evaluate the relationship between Disease-Free (DF) status and brain atrophyover 4 years from the fingolimod phase III FREEDOMS study and extension.

Method DF-status was defined as the maintained absence over 0–48 months of all the following: confirmed disability progression, confirmed relapses, new Gd-enhancing T1-lesions and new/enlarged T2-lesions; patients having any one or more of these measures were defined as not DF (nDF). In these posthocanalyses, Percentage Brain Volume Change (PBVC) during months 0–12, 0–24, 0–36 and 0–48 was dichotomized by DF-status at month-48 (DF or nDF) in the overall study population (OSP) and by treatment-group (fingolimod 0.5 mg; combined fingolimod 0.5 and 1.25 mg; and placebo-fingolimod patients [Plc-fingolimod]).

Results In the OSP, DF-patients had lower PBVC during the core-study and extension, versus nDF patients (DF/nDF): month 0–12, −0.17%/−0.60%; month 0–24, −0.53%/−1.14%; month 0–36, −0.94%/−1.52%; month 0–48−1.36%/−2.08%. Continuously-treated fingolimod 0.5mg patients had lower PBVC over month 0–48 versus switch patients: DF (fingolimod/Plc-fingolimod; % difference): −1.12%/−1.66%; 38.8%; nDF: −1.77%/−2.54%; 35.7%.

Conclusions Patients DF over 48-months experienced less brain volume loss (BVL) than nDF patients over 4-years. A treatment delay of 2 years with fingolimod was associated with more BVL.

  • EPILEPSY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.